S&P 500   3,918.97 (+0.97%)
DOW   31,937.03 (+1.27%)
QQQ   322.84 (+0.42%)
AAPL   124.52 (-1.06%)
MSFT   233.97 (+0.30%)
FB   265.09 (-0.29%)
GOOGL   2,076.90 (+0.81%)
AMZN   3,155.25 (-1.23%)
TSLA   727.20 (+4.06%)
NVDA   578.28 (+2.23%)
BABA   249.70 (-1.21%)
CGC   35.29 (-0.06%)
GE   13.28 (+5.48%)
MU   91.33 (+3.51%)
NIO   50.68 (+3.20%)
AMD   86.24 (+1.77%)
T   29.31 (+0.45%)
F   12.19 (+4.91%)
ACB   11.35 (+1.25%)
DIS   197.00 (-0.05%)
BA   226.42 (+6.74%)
NFLX   552.09 (+1.09%)
BAC   36.46 (+2.65%)
S&P 500   3,918.97 (+0.97%)
DOW   31,937.03 (+1.27%)
QQQ   322.84 (+0.42%)
AAPL   124.52 (-1.06%)
MSFT   233.97 (+0.30%)
FB   265.09 (-0.29%)
GOOGL   2,076.90 (+0.81%)
AMZN   3,155.25 (-1.23%)
TSLA   727.20 (+4.06%)
NVDA   578.28 (+2.23%)
BABA   249.70 (-1.21%)
CGC   35.29 (-0.06%)
GE   13.28 (+5.48%)
MU   91.33 (+3.51%)
NIO   50.68 (+3.20%)
AMD   86.24 (+1.77%)
T   29.31 (+0.45%)
F   12.19 (+4.91%)
ACB   11.35 (+1.25%)
DIS   197.00 (-0.05%)
BA   226.42 (+6.74%)
NFLX   552.09 (+1.09%)
BAC   36.46 (+2.65%)
S&P 500   3,918.97 (+0.97%)
DOW   31,937.03 (+1.27%)
QQQ   322.84 (+0.42%)
AAPL   124.52 (-1.06%)
MSFT   233.97 (+0.30%)
FB   265.09 (-0.29%)
GOOGL   2,076.90 (+0.81%)
AMZN   3,155.25 (-1.23%)
TSLA   727.20 (+4.06%)
NVDA   578.28 (+2.23%)
BABA   249.70 (-1.21%)
CGC   35.29 (-0.06%)
GE   13.28 (+5.48%)
MU   91.33 (+3.51%)
NIO   50.68 (+3.20%)
AMD   86.24 (+1.77%)
T   29.31 (+0.45%)
F   12.19 (+4.91%)
ACB   11.35 (+1.25%)
DIS   197.00 (-0.05%)
BA   226.42 (+6.74%)
NFLX   552.09 (+1.09%)
BAC   36.46 (+2.65%)
S&P 500   3,918.97 (+0.97%)
DOW   31,937.03 (+1.27%)
QQQ   322.84 (+0.42%)
AAPL   124.52 (-1.06%)
MSFT   233.97 (+0.30%)
FB   265.09 (-0.29%)
GOOGL   2,076.90 (+0.81%)
AMZN   3,155.25 (-1.23%)
TSLA   727.20 (+4.06%)
NVDA   578.28 (+2.23%)
BABA   249.70 (-1.21%)
CGC   35.29 (-0.06%)
GE   13.28 (+5.48%)
MU   91.33 (+3.51%)
NIO   50.68 (+3.20%)
AMD   86.24 (+1.77%)
T   29.31 (+0.45%)
F   12.19 (+4.91%)
ACB   11.35 (+1.25%)
DIS   197.00 (-0.05%)
BA   226.42 (+6.74%)
NFLX   552.09 (+1.09%)
BAC   36.46 (+2.65%)
Log in
NYSE:AMRX

Amneal Pharmaceuticals Stock Forecast, Price & News

$5.05
+0.25 (+5.21 %)
(As of 02/24/2021 02:12 PM ET)
Add
Compare
Today's Range
$4.85
Now: $5.05
$5.17
50-Day Range
$4.74
MA: $5.13
$5.91
52-Week Range
$2.40
Now: $5.05
$6.18
Volume25,567 shs
Average Volume1.35 million shs
Market Capitalization$1.51 billion
P/E Ratio12.32
Dividend YieldN/A
Beta1.27
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Amneal Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120
Employees5,500
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.18 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Market Cap$1.51 billion
Next Earnings Date2/26/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

368th out of 1,958 stocks

Pharmaceutical Preparations Industry

193rd out of 772 stocks

Analyst Opinion: 1.2Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 4.4 5 -4 -3 -2 -1 -
$5.05
+0.25 (+5.21 %)
(As of 02/24/2021 02:12 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

Is Amneal Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amneal Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRX, but not buy additional shares or sell existing shares.
View analyst ratings for Amneal Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Amneal Pharmaceuticals?

Wall Street analysts have given Amneal Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amneal Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totaling 6,090,000 shares, an increase of 19.4% from the December 31st total of 5,100,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 5.2 days. Currently, 6.4% of the shares of the company are short sold.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for Amneal Pharmaceuticals
.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Friday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its quarterly earnings results on Friday, November, 6th. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.04. The firm earned $519.30 million during the quarter, compared to analyst estimates of $482.22 million. Amneal Pharmaceuticals had a trailing twelve-month return on equity of 42.02% and a net margin of 3.30%. The business's revenue was up 37.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.04 EPS.
View Amneal Pharmaceuticals' earnings history
.

How has Amneal Pharmaceuticals' stock been impacted by COVID-19?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRX shares have increased by 55.4% and is now trading at $5.05.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AMRX?

8 brokers have issued 1 year target prices for Amneal Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they anticipate Amneal Pharmaceuticals' stock price to reach $4.88 in the next twelve months. This suggests that the stock has a possible downside of 3.5%.
View analysts' price targets for Amneal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Chirag K. Patel, Co-Founder, Co-CEO, Pres & Director (Age 54, Pay $62.97k)
  • Mr. Chintu Patel R.Ph., R.Ph, Co-Founder, Co-CEO & Director (Age 49, Pay $64.6k)
  • Mr. Andrew S. Boyer, Exec. VP & Chief Commercial Officer of Generics (Age 55, Pay $675.09k)
  • Mr. Anastasios G. Konidaris, Exec. VP & CFO (Age 54)
  • Mr. Stephen J. Manzano, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. James Luce, Exec. VP of Sales & Marketing
  • Ms. Nikita Shah, Exec. VP and Chief HR Officer & Strategic Planning Officer (Age 43)
  • Mr. Sanjiv Patel, Sr. VP of Operations
  • Ms. Candis Edwards, Sr. VP of Regulatory Affairs
  • Mr. Joseph Todisco MBA, Exec. VP & Chief Commercial Officer of Specialty (Age 45)

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals CEO Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among Amneal Pharmaceuticals' employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (2.47%), Northern Trust Corp (0.47%), THB Asset Management (0.34%), Bank of New York Mellon Corp (0.26%), Nuveen Asset Management LLC (0.19%) and Magnetar Financial LLC (0.18%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Peter R Terreri, Pradeep Bhadauria and Ted C Nark.
View institutional ownership trends for Amneal Pharmaceuticals
.

Which major investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Zacks Investment Management, Smith Asset Management Group LP, Globeflex Capital L P, Squarepoint Ops LLC, State of Wisconsin Investment Board, and Northern Trust Corp.
View insider buying and selling activity for Amneal Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Amneal Pharmaceuticals stock?

AMRX stock was acquired by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, JPMorgan Chase & Co., Assenagon Asset Management S.A., Brandywine Global Investment Management LLC, THB Asset Management, Nuveen Asset Management LLC, Renaissance Technologies LLC, and CM Management LLC. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Pradeep Bhadauria, and Ted C Nark.
View insider buying and selling activity for Amneal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $5.05.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals has a market capitalization of $1.51 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

Where are Amneal Pharmaceuticals' headquarters?

Amneal Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.